Ginkgo Bioworks Holdings Inc. Chief Financial Officer Steven P. Coen sold 330 Class A common shares on August 24, 2026, for a total of $2,302 at $6.977 per share.
The sale was executed as a sell-to-cover transaction to meet tax withholding obligations tied to the vesting of restricted stock units, according to filings. Coen had acquired 743 Class A shares on August 21, 2026, through the vesting of 587 units and 156 units under RSU schedules that began releasing on May 1, 2024. Following the transaction, Coen directly holds 51,851 Class A shares of the biotech firm.
Ginkgo Bioworks’ shares rose 11.21% intraday to $7.54, with a closing price of $7.54 and an after-hours quote of $7.57. The stock remains well below its 52-week high of $17.58.
The company’s second-quarter 2026 results showed an adjusted loss of $0.92 per share, narrower than the expected loss of $1.05, but revenue of $20 million missed the $29.9 million forecast. Year-over-year revenue declined 48%. Ginkgo Bioworks reported total liquidity of $389 million at the end of the quarter and maintained its annual cash burn guidance of $125 million to $150 million.
Analysts at TD Cowen downgraded the stock to Hold from Buy and reduced the price target to $9.00 from $12.00.
